Chikungunya, Dengue, and Zika in Immunocompromised Hosts

30Citations
Citations of this article
120Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose of Review: Describe the characteristics of chikungunya, dengue, and Zika in transplant recipients and immunocompromised hosts. Recent Findings: Stem cell/bone marrow grafts, organs, and blood transfusions can transmit CHIKV/DENV/ZIKV infections, which are clinically similar, resembling influenza-like illness. Laboratory confirmation is necessary. In the acute phase, RT-PCR is preferred. DENV and ZIKV serology may cross-react. Delayed engraftment and extended viruria is observed in ZIKV+/HSCT recipients, while longer viremia is observed in DENV+/HSCT patients. Arbovirus persistence in organ tissues is generally unknown. Vaccine development is in early stages for CHIKV/ZIKV. No data is available to recommend the licensed DENV vaccine in transplant recipients. Summary: In endemic areas, the assessment of epidemiological risk is mandatory. Donor deferral for 120 days in suspected or confirmed ZIKV+ has been recommended, while CHIKV+ donors should wait 30 days. No deferral is recommended for DENV+ donors. CHIKV/DENV/ZIKV tests should be included in the differential of febrile neutropenia and other transplant syndromes. Reassessment of DENV serology is urgently needed. Prospective studies are necessary to determine the impact of CHIKV/DENV/ZIKV in this special population.

Cite

CITATION STYLE

APA

Darrigo, L. G., de Sant’Anna Carvalho, A. M., & Machado, C. M. (2018, April 1). Chikungunya, Dengue, and Zika in Immunocompromised Hosts. Current Infectious Disease Reports. Current Medicine Group LLC 1. https://doi.org/10.1007/s11908-018-0612-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free